After signing up, you'll start to receive regular news updates from us.
GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM® Project
Complete the form below to unlock access to ALL audio articles.
GENEART and MorphoSys announce their successful cooperation in the HuCAL PLATINUM® project. The application of GENEART's proprietary sequence design software GeneOptimizer® and production of significant parts of the antibody library allowed GENEART to make a large contribution to this project.
Initial tests show that the HuCAL PLATINUM® translates into an up to 25 fold higher diversity compared to the previous version HuCAL GOLD®, and thereby provides more divers fully human antibodies as well as facilitating the selection of antibodies with a higher average affinity.
Due to comprehensive sequence optimization, production rates of selected antibodies are significantly higher as well. Therefore, this next-generation antibody library does not only allow the identification of antibodies with improved characteristics but also the significant shortening of timelines for the development of promising drug candidates to pre-clinical studies.
"In GENEART we found the right partner in the field of DNA Engineering and Directed Evolution for this complex project. The high quality of the gene libraries produced and GENEART's sequence optimization were essential requirements for the realization of HuCAL PLATINUM®'s increased diversity and improved expression rates", explained Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
HuCAL PLATINUM® contains the genetic information of approximately 45 billion fully human antibodies. By using the GeneOptimizer® GENEART largely eliminated DNA motifs identified as potentially distracting the subsequent production of antibodies.
Additionally, MorphoSys eliminated limiting motifs at the protein level. This resulted in doubling the production rate of selected antibodies, which is expected to reduce the timeline of projects involving the generation of antibodies.
